Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Era+ breast cancer patients often develop resistance to endocrine therapy. Here, the authors show that FGFR1 amplification is a resistance mechanism to CDK4/6 inhibitor and endocrine therapy and that combined treatment with FGFR, CDK4/6, and anti-estrogens is a potential therapeutic strategy in Era+...

Full description

Bibliographic Details
Main Authors: Luigi Formisano, Yao Lu, Alberto Servetto, Ariella B. Hanker, Valerie M. Jansen, Joshua A. Bauer, Dhivya R. Sudhan, Angel L. Guerrero-Zotano, Sarah Croessmann, Yan Guo, Paula Gonzalez Ericsson, Kyung-min Lee, Mellissa J. Nixon, Luis J. Schwarz, Melinda E. Sanders, Teresa C. Dugger, Marcelo Rocha Cruz, Amir Behdad, Massimo Cristofanilli, Aditya Bardia, Joyce O’Shaughnessy, Rebecca J. Nagy, Richard B. Lanman, Nadia Solovieff, Wei He, Michelle Miller, Fei Su, Yu Shyr, Ingrid A. Mayer, Justin M. Balko, Carlos L. Arteaga
Format: Article
Language:English
Published: Nature Publishing Group 2019-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-09068-2

Internet

https://doi.org/10.1038/s41467-019-09068-2

Similar Items